Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Hancock Jaffe Laboratories (NASDAQ:HJLI) will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 1:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hancock Jaffe Laboratories (NASDAQ:HJLI) will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 1:00 PM ET. CEO Robert Berman will deliver the presentation, and the management team will conduct virtual one-on-one meetings for registered investors.
A live webcast of the presentation will be available on the Company's Investors page and archived for 90 days. Hancock Jaffe specializes in bioprosthetic medical devices aimed at improving cardiac and vascular health.
Details
News Market Reaction – HJLI
The recorded move for HJLI in the trading session of this news was -2.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast on Tuesday, July 13th at 1:00 PM ET
IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Robert Berman, CEO of Hancock Jaffe will present at the Ladenburg Thalmann 2021 Healthcare Conference on Tuesday, July 13, 2021 at 1:00 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of Mr. Berman's presentation will be available on the Events page of the Investors section on the Company's website (www.hancockjaffe.com) and will be archived for 90 days following the event.
About Hancock Jaffe Laboratories, Inc.
Hancock Jaffe Laboratories (NASDAQ:HJLI) specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve®, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraft®, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
HJLI@jtcir.com
(833) 475-8247
MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 902-1274
SOURCE: Hancock Jaffe Laboratories, Inc.
View source version on accesswire.com:
https://www.accesswire.com/654665/Hancock-Jaffe-to-Present-at-the-Ladenburg-Thalmann-2021-Healthcare-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.